Incyte plans to buy Star Therapeutics and its Phase 3 bleeding disorder candidate.
Incyte plans to spend $1.25 billion upfront to buy Star Therapeutics’ subsidiary Vega Therapeutics and its Phase 3 bleeding disorder candidate, the companies said Monday …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential - Incyte (NASDAQ:INCY
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Incyte to buy blood disorder drug in possibly $2B deal
Incyte compra Vega Therapeutics por até US$ 2 bi para expandir portfólio em hematologia
Novo underwhelmed by drug it once fought Pfizer for
Alnylam, Inceptive ink AI deal potentially worth $2B
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
Health Care Ticks Down Amid Deal Activity - Health Care Roundup
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
Incyte to acquire Vega Therapeutics for $1.25 billion upfront, adding a rare bleeding disorder candidate with blockbuster…
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into…
Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in…
Incyte CEO Bill Meury acquires Vega Therapeutics for up to $2B, adding Phase 3 von Willebrand disease drug as Jakafi faces 2028…
A aquisição inclui o principal projeto da Vega, o VGA039, que modula a Proteína S para melhorar a hemostasia, aumentando…
Delaware-based Incyte is now turning to AI to power through the coming decades.
